Publications by authors named "Jonathan A Leff"

Claim this Profile
A
A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults.
David B Karpf, Susanne Pihl, Sanchita Mourya, Eva Mortensen, Eshwari Kovoor, Jonathan A Leff

J Bone Miner Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-man phase 1 trial for long-acting TransCon Growth Hormone.
David Gilfoyle, Eva Mortensen, Eva Dam Christoffersen, Jonathan A Leff, Michael Beckert

Growth Horm IGF Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency.
Kennett Sprogøe, Eva Mortensen, David B Karpf, Jonathan A Leff

Endocr Connect· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
Pierre Chatelain, Oleg Malievskiy, Klaudziya Radziuk, Ganna Senatorova, Magdy O Abdou, Jonathan A Leff

J Clin Endocrinol Metab· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency.
Charlotte Höybye, Andreas F H Pfeiffer, Diego Ferone, Jens Sandahl Christiansen, David Gilfoyle, Jonathan A Leff

Endocr Connect· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Jonathan A Leff

Eur Respir J· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma.
Nestor A Molfino, Piotr Kuna, Jonathan A Leff, Chad K Oh, Dave Singh

BMJ Open· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward.
Eric S White, Kevin K Brown, Harold R Collard, Craig S Conoscenti, Gregory P Cosgrove, Jonathan A Leff

Ann Am Thorac Soc· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
Dominique Valeyre, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Talmadge E King, Jonathan A Leff

Respirology· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
Roland M du Bois, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Jonathan A Leff

Eur Respir J· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
Talmadge E King, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Jonathan A Leff

Am J Respir Crit Care Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis.
Williamson Z Bradford, Alan H Cohen, Jonathan A Leff

Am J Respir Crit Care Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
Alyssa K Johnsen, Michael H Schiff, Philip J Mease, Larry W Moreland, Agnes L Maier, Jonathan A Leff

J Rheumatol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Allan Gibofsky, William R Palmer, John A Goldman, Richard L Lautzenheiser, Joseph A Markenson, Jonathan A Leff

Curr Med Res Opin· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Arthur L Weaver, Richard L Lautzenheiser, Michael H Schiff, Allan Gibofsky, James L Perruquet, Jonathan A Leff

Curr Med Res Opin· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
Mark C Genovese, Joan M Bathon, Roy M Fleischmann, Larry W Moreland, Richard W Martin, Jonathan A Leff

J Rheumatol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Boulos Haraoui, Edward C Keystone, J Carter Thorne, Janet E Pope, Isaac Chen, Jonathan A Leff

J Rheumatol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
Leif Bjermer, Hans Bisgaard, Jean Bousquet, Leonardo M Fabbri, Andrew P Greening, Jonathan A Leff

BMJ· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3.
Bifeng Gao, Sonia C Flores, Jonathan A Leff, Swapan K Bose, Joe M McCord

Am J Physiol Lung Cell Mol Physiol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis